Clinical Trial Update: Efficacy and Safety of CRT, Durvalumab and Surgery for SST [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CRT, durvalumab, and surgery for superior sulcus tumor in non-small cell lung cancer (stage IIB/III).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Superior Sulcus Tumor

Drugs mentioned

• CRT
• Durvalumab (durvalumab)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB | Phase 3 | Status: NOT_YET_RECRUITING